Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
IBM Watson, Microsoft, Oracle, GE are among the dozens, if not hundreds, of companies that are developing and deploying game-changing technologies, tools, services, and processes focused on transforming how clinical trials are conducted. The goals are lofty, and the stakes are high: patients are waiting for safe, efficacious, and in some cases, life-saving treatments.
At eyeforpharma’s Third Annual Data & Technology in Clinical Trials USA conference, recently held in Philadelphia, the concept of re-designing clinical trials so they don’t just determine safety and efficacy but also provide key information about the patient experience of a drug in order to bring better products to market was the key focus of dozens of industry leaders. They addressed a number of related topics, including ways to turn clinical trials from an expensive burden into a differentiating asset, and how to build smarter, more effective strategies by combining big data with sophisticated analytics and real-time feedback. (For more information, visit http://www.eyeforpharma.com/data-clinical/.)
As we prepare for the 2017 DIA Annual Meeting next month in Chicago (stop by PharmaVOICE’s booth #715 to say hello) and look forward to seeing first-hand the various technologies that are currently being employed in the clinical trial space, we wanted to turn the focus of this month’s cover story to the successes that biopharma companies and their technology partners are having as they collaboratively make significant strides to impact R&D efficiency, accelerate time to market, improve safety, and boost data accuracy. We learned making much of this transformation possible are cloud-based technologies, ramped-up computing power, and increasingly more sophisticated machine learning and algorithms.
Experts say at the heart of trial transformation are data. As Denise Myshko reports, in the future fewer data points will come from the traditional investigator-led EDC data entry process, and the ability to pool real-world data evidence information from payers, insurance companies, EMR systems, wearables, etc., and the application of analytics against this crucial intelligence will become the new normal.
We further explore trial technology solution trends in this month’s special Showcase Clinical Trial Solutions Forum featuring several of the industry’s leading clinical trial tansformers — ACM Global, Advanced Clinical, Atlantic Research Group, Axiom Real-Time Metrics, Clincierge, Cognizant, DrugDev, ERT, ICON, KellyOCG, Lifelines Neurodiagnostic Systems, Medidata, and Medpace — who note that the market and range of clinical trial solutions continue to grow and adapt to changing needs and capabilities, including mobile technologies and cloud deployment. It’s no surprise that the continued pressure to bring products to market faster and to reduce the cost of clinical trials, while improving recruitment and data collection, will drive greater uptake of advanced clinical trial solutions. And the market is growing fast. Global industry analysts predict that the market for eClinical solutions alone will reach $7.61 billion by 2022, a CAGR of 12.4%.
Taren Grom, Editor
Biopharma companies and their partners are making significant strides with technology efforts to impact R&D efficiency and boost data accuracy.
The requirements for developing successful relationships are based on trust, respect, and transparency.
Rare diseases face some unique logistical challenges, making precise planning a priority for companies making these products.
Coming in July/August 2017
The July/August issue features 100 of the most inspiring individuals in the life-sciences industry as determined by you, our readers. These individuals demonstrate what it means to think bigger, do more, and lead with passion and integrity.
Don’t miss this issue to see who is on the list!
Volume 17 • Number 6
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh
Director of Sales
National Account Manager
Webcast Network Producer
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Seventeen, Number Six
PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.
Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.
PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.
Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: firstname.lastname@example.org.
Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: email@example.com.
Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.
Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O. Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: firstname.lastname@example.org.